Do analysts prefer LIMN or NEUP?

Neuphoria Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 102.90%. Given Neuphoria Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Neuphoria Therapeutics is more favorable than Liminatus Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Neuphoria Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is LIMN or NEUP more profitable?

Liminatus Pharma's return on equity of 0.00% beat Neuphoria Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Liminatus Pharma N/A N/A -256.58% Neuphoria Therapeutics N/A -38.31% -28.92%

Do analysts prefer GNTA or LIMN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, GNTA or LIMN?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genenta Science N/A N/A -$7.39M N/A N/A Liminatus Pharma N/A N/A -$10.21M -$23.50 N/A

Is GNTA or LIMN more profitable?

Company Net Margins Return on Equity Return on Assets Genenta Science N/A N/A N/A Liminatus Pharma N/A N/A -256.58%

Do analysts recommend LIMN or NXTC?

NextCure has a consensus price target of $19.00, suggesting a potential upside of 234.51%. Given NextCure's stronger consensus rating and higher probable upside, analysts plainly believe NextCure is more favorable than Liminatus Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NextCure 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has stronger valuation and earnings, LIMN or NXTC?

NextCure is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liminatus Pharma N/A N/A -$10.21M -$23.50 N/A NextCure N/A N/A -$55.84M -$8.70 N/A

Is LIMN or NXTC more profitable?

Liminatus Pharma's return on equity of 0.00% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets Liminatus Pharma N/A N/A -256.58% NextCure N/A -154.62% -100.19%

Do analysts rate AKTX or LIMN?

Akari Therapeutics presently has a consensus target price of $32.33, indicating a potential upside of 285.38%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Akari Therapeutics is more favorable than Liminatus Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akari Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, AKTX or LIMN?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akari Therapeutics N/A N/A -$17.30M N/A N/A Liminatus Pharma N/A N/A -$10.21M -$23.50 N/A

Is AKTX or LIMN more profitable?

Liminatus Pharma's return on equity of 0.00% beat Akari Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Akari Therapeutics N/A -147.45% -74.70% Liminatus Pharma N/A N/A -256.58%

Does the media prefer AKTX or LIMN?

In the previous week, Akari Therapeutics had 1 more articles in the media than Liminatus Pharma. MarketBeat recorded 3 mentions for Akari Therapeutics and 2 mentions for Liminatus Pharma. Liminatus Pharma's average media sentiment score of 0.33 beat Akari Therapeutics' score of 0.07 indicating that Liminatus Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akari Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Liminatus Pharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate LIMN or MRKR?

Marker Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 890.10%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Marker Therapeutics is more favorable than Liminatus Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Marker Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is LIMN or MRKR more profitable?

Liminatus Pharma's return on equity of 0.00% beat Marker Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Liminatus Pharma N/A N/A -256.58% Marker Therapeutics N/A -56.96% -47.82%

Liminatus Pharma (LIMN) Competitors

$3.81 +0.11 (+2.92%)

As of 01:51 PM Eastern

Compare

LIMN vs. NEUP, GNTA, NXTC, AKTX, and MRKR

Should you buy Liminatus Pharma stock or one of its competitors? Liminatus Pharma's main competitors and comparable companies include Neuphoria Therapeutics (NEUP), Genenta Science (GNTA), NextCure (NXTC), Akari Therapeutics (AKTX), and Marker Therapeutics (MRKR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Liminatus Pharma compare to Neuphoria Therapeutics?

Liminatus Pharma (NASDAQ:LIMN) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability.

Neuphoria Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 102.90%. Given Neuphoria Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Neuphoria Therapeutics is more favorable than Liminatus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Liminatus Pharma has a beta of 4.97, indicating that its share price is 397% more volatile than the broader market. Comparatively, Neuphoria Therapeutics has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market.

In the previous week, Liminatus Pharma had 2 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 2 mentions for Liminatus Pharma and 0 mentions for Neuphoria Therapeutics. Liminatus Pharma's average media sentiment score of 0.33 beat Neuphoria Therapeutics' score of 0.00 indicating that Liminatus Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Liminatus Pharma	Neutral
Neuphoria Therapeutics	Neutral

Liminatus Pharma's return on equity of 0.00% beat Neuphoria Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-256.58%
Neuphoria Therapeutics	N/A	-38.31%	-28.92%

15.9% of Neuphoria Therapeutics shares are held by institutional investors. 19.4% of Liminatus Pharma shares are held by insiders. Comparatively, 1.6% of Neuphoria Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Liminatus Pharma has higher earnings, but lower revenue than Neuphoria Therapeutics. Neuphoria Therapeutics is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liminatus Pharma	N/A	N/A	-$10.21M	-$23.50	N/A
Neuphoria Therapeutics	$1.17M	15.90	-$13.45M	-$6.22	N/A

Summary

Liminatus Pharma beats Neuphoria Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Liminatus Pharma compare to Genenta Science?

Genenta Science (NASDAQ:GNTA) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

In the previous week, Liminatus Pharma had 2 more articles in the media than Genenta Science. MarketBeat recorded 2 mentions for Liminatus Pharma and 0 mentions for Genenta Science. Liminatus Pharma's average media sentiment score of 0.33 beat Genenta Science's score of 0.00 indicating that Liminatus Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Genenta Science	Neutral
Liminatus Pharma	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
Liminatus Pharma	N/A	N/A	-256.58%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Genenta Science has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Liminatus Pharma has a beta of 4.97, meaning that its stock price is 397% more volatile than the broader market.

15.1% of Genenta Science shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by insiders. Comparatively, 19.4% of Liminatus Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A
Liminatus Pharma	N/A	N/A	-$10.21M	-$23.50	N/A

Summary

Genenta Science beats Liminatus Pharma on 4 of the 7 factors compared between the two stocks.

How does Liminatus Pharma compare to NextCure?

Liminatus Pharma (NASDAQ:LIMN) and NextCure (NASDAQ:NXTC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Liminatus Pharma has a beta of 4.97, meaning that its stock price is 397% more volatile than the broader market. Comparatively, NextCure has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market.

NextCure is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liminatus Pharma	N/A	N/A	-$10.21M	-$23.50	N/A
NextCure	N/A	N/A	-$55.84M	-$8.70	N/A

In the previous week, Liminatus Pharma had 2 more articles in the media than NextCure. MarketBeat recorded 2 mentions for Liminatus Pharma and 0 mentions for NextCure. Liminatus Pharma's average media sentiment score of 0.33 beat NextCure's score of 0.00 indicating that Liminatus Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Liminatus Pharma	Neutral
NextCure	Neutral

NextCure has a consensus price target of $19.00, suggesting a potential upside of 234.51%. Given NextCure's stronger consensus rating and higher probable upside, analysts plainly believe NextCure is more favorable than Liminatus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Liminatus Pharma's return on equity of 0.00% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-256.58%
NextCure	N/A	-154.62%	-100.19%

42.7% of NextCure shares are held by institutional investors. 19.4% of Liminatus Pharma shares are held by insiders. Comparatively, 11.9% of NextCure shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Liminatus Pharma beats NextCure on 7 of the 13 factors compared between the two stocks.

How does Liminatus Pharma compare to Akari Therapeutics?

Akari Therapeutics (NASDAQ:AKTX) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A
Liminatus Pharma	N/A	N/A	-$10.21M	-$23.50	N/A

In the previous week, Akari Therapeutics had 1 more articles in the media than Liminatus Pharma. MarketBeat recorded 3 mentions for Akari Therapeutics and 2 mentions for Liminatus Pharma. Liminatus Pharma's average media sentiment score of 0.33 beat Akari Therapeutics' score of 0.07 indicating that Liminatus Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akari Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Liminatus Pharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Liminatus Pharma's return on equity of 0.00% beat Akari Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akari Therapeutics	N/A	-147.45%	-74.70%
Liminatus Pharma	N/A	N/A	-256.58%

Akari Therapeutics has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market. Comparatively, Liminatus Pharma has a beta of 4.97, meaning that its share price is 397% more volatile than the broader market.

Akari Therapeutics presently has a consensus target price of $32.33, indicating a potential upside of 285.38%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Akari Therapeutics is more favorable than Liminatus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akari Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

5.1% of Akari Therapeutics shares are owned by institutional investors. 30.0% of Akari Therapeutics shares are owned by company insiders. Comparatively, 19.4% of Liminatus Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Akari Therapeutics beats Liminatus Pharma on 8 of the 12 factors compared between the two stocks.

How does Liminatus Pharma compare to Marker Therapeutics?

Liminatus Pharma (NASDAQ:LIMN) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Liminatus Pharma has a beta of 4.97, suggesting that its stock price is 397% more volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market.

Liminatus Pharma has higher earnings, but lower revenue than Marker Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liminatus Pharma	N/A	N/A	-$10.21M	-$23.50	N/A
Marker Therapeutics	$3.55M	4.74	-$12.16M	-$0.41	N/A

Liminatus Pharma's return on equity of 0.00% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-256.58%
Marker Therapeutics	N/A	-56.96%	-47.82%

22.4% of Marker Therapeutics shares are held by institutional investors. 19.4% of Liminatus Pharma shares are held by company insiders. Comparatively, 5.7% of Marker Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Marker Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 890.10%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Marker Therapeutics is more favorable than Liminatus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Liminatus Pharma had 2 more articles in the media than Marker Therapeutics. MarketBeat recorded 2 mentions for Liminatus Pharma and 0 mentions for Marker Therapeutics. Liminatus Pharma's average media sentiment score of 0.33 beat Marker Therapeutics' score of 0.00 indicating that Liminatus Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Liminatus Pharma	Neutral
Marker Therapeutics	Neutral

Summary

Liminatus Pharma and Marker Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Liminatus Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LIMN vs. The Competition

Export

Metric	Liminatus Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.08M	$3.88B	$7.23B	$13.34B
Dividend Yield	N/A	3.65%	2.53%	17.39%
P/E Ratio	-0.16	13.42	275.15	26.18
Price / Sales	N/A	1,239.10	636.44	107.19
Price / Cash	N/A	126.56	79.41	53.24
Price / Book	-0.21	16.07	10.79	6.29
Net Income	-$10.21M	-$22.68M	$3.50B	$382.03M
7 Day Performance	2.09%	-4.05%	-1.23%	-0.82%
1 Month Performance	2.64%	-12.10%	-6.39%	-5.28%
1 Year Performance	-95.18%	13.84%	6.17%	0.84%

Liminatus Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LIMN Liminatus Pharma	0.7446 of 5 stars	$3.81 +2.9%	N/A	-95.7%	$5.08M	N/A	N/A	1
NEUP Neuphoria Therapeutics	2.046 of 5 stars	$3.54 -0.7%	$7.00 +98.0%	-82.8%	$19.12M	$1.17M	N/A	8
GNTA Genenta Science	0.8595 of 5 stars	$0.81 +15.7%	N/A	-75.8%	$19.11M	N/A	N/A	9	Positive News
NXTC NextCure	2.7554 of 5 stars	$5.12 +2.3%	$19.00 +270.9%	-5.3%	$18.46M	N/A	N/A	40	News Coverage
AKTX Akari Therapeutics	3.2924 of 5 stars	$9.29 -0.2%	$32.33 +248.2%	-79.5%	$18.08M	N/A	N/A	5	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LIMN) was last updated on 10/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Liminatus Pharma (LIMN) Competitors

LIMN vs. NEUP, GNTA, NXTC, AKTX, and MRKR

How does Liminatus Pharma compare to Neuphoria Therapeutics?

Summary

How does Liminatus Pharma compare to Genenta Science?

Summary

How does Liminatus Pharma compare to NextCure?

Summary

How does Liminatus Pharma compare to Akari Therapeutics?

Summary

How does Liminatus Pharma compare to Marker Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIMN vs. The Competition

Liminatus Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Liminatus Pharma (LIMN) Competitors

LIMN vs. NEUP, GNTA, NXTC, AKTX, and MRKR

How does Liminatus Pharma compare to Neuphoria Therapeutics?

Do analysts prefer LIMN or NEUP?

Which has more volatility & risk, LIMN or NEUP?

Does the media favor LIMN or NEUP?

Is LIMN or NEUP more profitable?

Do insiders and institutionals have more ownership in LIMN or NEUP?

Which has higher valuation & earnings, LIMN or NEUP?

Summary

How does Liminatus Pharma compare to Genenta Science?

Does the media prefer GNTA or LIMN?

Is GNTA or LIMN more profitable?

Do analysts prefer GNTA or LIMN?

Which has more volatility and risk, GNTA or LIMN?

Do insiders & institutionals have more ownership in GNTA or LIMN?

Which has preferable valuation & earnings, GNTA or LIMN?

Summary

How does Liminatus Pharma compare to NextCure?

Which has more volatility & risk, LIMN or NXTC?

Which has stronger valuation and earnings, LIMN or NXTC?

Does the media favor LIMN or NXTC?

Do analysts recommend LIMN or NXTC?

Is LIMN or NXTC more profitable?

Do institutionals and insiders hold more shares of LIMN or NXTC?

Summary

How does Liminatus Pharma compare to Akari Therapeutics?

Which has stronger valuation & earnings, AKTX or LIMN?

Does the media prefer AKTX or LIMN?

Is AKTX or LIMN more profitable?

Which has more volatility & risk, AKTX or LIMN?

Do analysts rate AKTX or LIMN?

Do institutionals & insiders believe in AKTX or LIMN?

Summary

How does Liminatus Pharma compare to Marker Therapeutics?

Which has more risk and volatility, LIMN or MRKR?

Which has higher valuation and earnings, LIMN or MRKR?

Is LIMN or MRKR more profitable?

Do insiders & institutionals have more ownership in LIMN or MRKR?

Do analysts rate LIMN or MRKR?

Does the media favor LIMN or MRKR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIMN vs. The Competition

Liminatus Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools